Incyte hires Janssen exec as CSO Huber moves to Third Rock; Synthorx set terms for $100M IPO
→ Ahead of an FDA decision on its key drug Jakafi’s use in graft vs. host disease, Incyte $INCY has lost its chief scientific officer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
